

ISSN 2664-472X


e ISSN 2664-4738

Medical Science of Ukraine

Медична наука України

2024, Vol. 20, № 3

Medical Science of Ukraine. 2024, vol. 20, № 3



Medical Science of Ukraine

Медична наука України

2024. Т. 20, № 3

Національний медичний університет імені О.О. Богомольця

<https://doi.org/10.32345/2664-4738.1.2024>

Періодичність видання – 1 раз на квартал

ЗМІСТ МЕДИЦИНА		CONTENT MEDICINE
<i>Марушко Є. Ю., Маньковський Г. Б., Джунь Я. Ю.</i> Мікрovasкулярна стенокардія як причина ішемічної хвороби серця при відсутності значимого атеросклеротичного ураження коронарних артерій	4	<i>Marushko E. Yu., Mankovsky G.B., Dzhun Ya.Yu</i> Microvascular angina in patients with non-stenotic coronary lesions
<i>Годік О.С.</i> Дистальний спленоренальний шунт при хірургічному лікуванні портальної гіпертензії у дітей	9	<i>Godik O. S.</i> Distal splenorenal shunt in surgical treatment of portal hypertension in children
<i>Кубрак М. А., Завгородній С. М., Данілюк М. Б.</i> Використання ендоскопічних методів у комплексі лікування пацієнтів з ускладненими формами раку товстого кишківника	16	<i>Kubrak M. A., Zavgorodnii S. M., Danilyk M. B.</i> Using of endoscopic methods in the treatment of patients with complicated forms of colon cancer
<i>Романюк О.Т., Склярєва О.Є., Тютюник О.О., Фоменко І.С., Склярєв Є.Я., Кобилінська Л.І., Варі Ш.Ж.</i> Роль адипонектину, вісфатину та ірису в патогенезі та лікуванні артеріальної гіпертензії	24	<i>Romaniuk O.T., Sklyarova H.E., Tiutiunyk O.O., Fomenko I.S., Sklyarov E.Y., Kobylinska L.I., VariShandor G</i> The role of adiponectin, visfatin and irisin in the pathogenesis and treatment of arterial hypertension
<i>Сук С.А.</i> Особливості розвитку і клінічного перебігу діабетичного макулярного набряку легкого ступеня тяжкості при цукровому діабеті 2 типу	34	<i>Suk S.A.</i> Features of the development and clinical course of mild diabetic macular edema in type 2 diabetes
<i>Соколенко М.О.</i> Неспецифічний протиінфекційний захист у хворих на COVID-19 залежно від поліморфізму генів, тяжкості захворювання і коморбідної патології	44	<i>Sokolenko M.O.</i> Nonspecific antiinfective protection in patients with COVID-19 depending on gene polymorphism, disease severity and comorbidity
<i>Ряба О.В., Чалий К.О., Голубовська О.А.</i> Оцінка ризиків летальності від захворювання на COVID-19 у госпіталізованих вакцинованих пацієнтів та пацієнтів після попередньо перенесеного захворювання в залежності від віку	53	<i>Riaba O.V., Chalyy K.O. Golubovska O.A</i> Assessment of mortality risks from COVID-19 in hospitalised vaccinated patients and patients after a previous illness depending on age

- diagnostic criteria for microvascular angina. *Int J Cardiol.* 2018; 250:16-20. DOI: 10.1016/j.ijcard.2017.08.068
4. Pacheco Claudio C, Quesada O, Pepine CJ, Noel Bairey Merz C. Why names matter for women: MINOCA/INOCA (myocardial infarction/ ischemia and no obstructive coronary artery disease). *Clin Cardiol.* 2018;41(2):185-193. DOI: 10.1002/clc.22894
 5. Tjoe B, Barsky L, Wei J, Samuels B, Azarbal B, et al. Coronary microvascular dysfunction: Considerations for diagnosis and treatment. *Cleve Clin J Med.* 2021;88(10):561-571. DOI: 10.3949/ccjm.88a.20140
 6. Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, et al.; ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. *Eur Heart J.* 2020;41(3): 407-477. DOI: 10.1093/eurheartj/ehz425
 7. Bairey Merz CN, Pepine CJ, Shimokawa H, Berry C. Treatment of coronary microvascular dysfunction. *Cardiovasc Res.* 2020; 116(4):856-870. DOI: 10.1093/cvr/cvaa006
 8. Sucato V, Madaudo C, Galassi AR. Classification, Diagnosis, and Treatment of Coronary Microvascular Dysfunction. *J Clin Med.* 2022 Aug 8;11(15):4610. DOI: 10.3390/jcm11154610
 9. Taqueti VR, Solomon SD, Shah AM, Desai AS, Groarke JD, et al. Coronary microvascular dysfunction and future risk of heart failure with preserved ejection fraction. *Eur Heart J.* 2018; 39(10): 840-849. DOI: 10.1093/eurheartj/ehx721

Article history:

Received: 12.07.2024

Revision requested: 15.07.2024

Revision received: 25.08.2024

Accepted: 25.09.2024

Published: 30.09.2024

MICROVASCULAR ANGINA IN PATIENTS WITH NON-STENOTIC CORONARY LESIONS

Marushko E. Yu., Mankovsky G.B., Dzhun Ya. Yu.

Government Institution The Scientific and Practical Medical Center of Pediatric Cardiology and Cardiac Surgery of the Ministry of Health of Ukraine, Kyiv, Ukraine

ievgen.marushko@gmail.com

Background. According to various literature data, from 1/3 to 1/2 of patients whose complaints correspond to a typical picture of angina pectoris do not have obstructive lesions of the coronary vessels during invasive coronary angiography. These patients belong to the INOCA group. The main pathogenic mechanism of this problem is coronary microvascular dysfunction (CMD), which manifests as a violation of the coronary vasodilation reserve.

Aim: to evaluate reserve of coronary vasodilatation and to determine the echocardiographic signs of myocardial ischemia in patients with angina pectoris and non-stenotic atherosclerosis of the coronary vessels according to the data of invasive coronary angiography.

Materials and methods. We included 311 patients with a clinical diagnosis of «CAD: angina pectoris» who underwent invasive coronary angiography and who had intact coronary arteries or non-stenotic lesions were consecutively examined. Coronary microvascular dysfunction (reduced iCFR index) occurred in 78.1% of patients with coronary heart disease without hemodynamically significant lesions of the coronary arteries. In those patients, a significant decrease in the GLS indicator was observed $-15.2 \pm 0.5\%$ compared to the baseline $-20.5 \pm 0.4\%$ mainly due to segmental disorders - signs of myocardial ischemia.

Conclusion. Stress echocardiography with strain imaging during intravenous dipyridamole was an effective method for simultaneously detecting violation of the coronary vasodilatation reserve and confirming the myocardial ischemia.

Key words: coronary heart disease, microvascular angina, coronary microvascular dysfunction, stress echocardiography, coronary blood flow reserve index.

DISTAL SPLENORENAL SHUNT IN SURGICAL TREATMENT OF PORTAL HYPERTENSION IN CHILDREN

Godik O. S. <https://orcid.org/0000-0002-1084-9484>

*Bogomolets National Medical University, Kyiv, Ukraine;
National Specialized Children's Hospital "Ohmatdyt", Kyiv, Ukraine*

ogodik@gmail.com

Background. Management of pediatric patients with portal hypertension (PH) has evolved considerably in recent years. Physiologic shunts and successful liver transplant has changed the paradigm of portal hypertension surgery. However, pediatric patients with noncirrhotic causes of PH and unfavorable anatomy, and patients with cirrhotic causes require other radical surgical approaches. There is a lack of publications on pediatric cohorts in which other surgical procedures, including DSRS, was performed.

Aim: to analyze effectiveness of DSRS in treatment of most dangerous PH symptoms: esophageal varices grade and bleeding episodes recurrence, splenomegaly, thrombocytopenia and anemia, and to assess DSRS survival in different groups of patients.

Materials and methods. A single-center retrospective study was performed. In 37 children underwent distal splenoportal shunt (DSRS) was performed in the period from January 2011 to January 2022. The mean follow-up period was 55.4±6.1 months.

Results. Patients of the study group (n=37,100%) were divided into two groups according to etiological factor, that caused PH: 29 (78.3%) were diagnosed EHPVO, and 8 (21.7%) – HPH. Comparison showed difference in spleen volume (p=0.009) and follow-up duration (p=0.001). DSRS resolved thrombocytopenia, anemia and decreased the spleen size in all the patients, platelets count increase in patients of both EHPVO (p=0.009) and HPH patients (p=0.021) and hemoglobin level increase in EHPVO patients (p=0.037). Varices grade comparison showed involution in both groups (p<0,001). However, DSRS dysfunction was observed in 8 (28.5%) patients from EHPVO group and in 1(12.5%) in HPH group. DSRS survival in EHPVO patients was assessed 0.309 (95%CI 0.0186-0.708) with no difference in overall shunt survival between groups.

Conclusion. DSRS showed good results in resolving dangerous symptoms of PH in both study groups with non-cirrhotic (EHPVO) and cirrhotic (HPH) causes of PH, with significant thrombocyte count increase and varices grade involution. However, despite no difference was found in DSRS survival between study groups, DSRS survival in patients with EHPVO reached median survival by 136 months.

Key words: portal hypertension, distal splenoportal shunt, shunt dysfunction, recurrent variceal bleeding, children.

Background. Management of pediatric patients with portal hypertension (PH) has evolved considerably in recent years. Development of physiologic shunts (meso-Rex bypass) and successful liver transplant has changed the paradigm of portal hypertension surgery. [1]. Surgical treatment is typically reserved for those patients who have failed medical and endoscopic measures, or who have significant sequela of portal venous hypertension, including significant splenomegaly [2]. While it is world-wide accepted, that children with extrahepatic portal vein obstruction (EHPVO) and PH that results from it are to be investigated and, if suitable, offered the mesenteric-to-left portal vein bypass [3,4], for children with hepatic form of portal

hypertension (HPH), other words it is in the setting of decompensated liver disease it is mostly offered to manage medically (via endoscopy) or radiologically (via transjugular intrahepatic portosystemic shunt) with the aim to offer liver transplant after this initial treatment [1,2,5]. There is a lack of publications on pediatric cohorts in which other surgical procedures, including DSRS, was performed.

Aim: to analyze effectiveness of DSRS in treatment of most dangerous PH symptoms: esophageal varices grade and bleeding episodes recurrence, splenomegaly, thrombocytopenia and anemia, and to assess DSRS survival in different groups of patients.

MATERIALS AND METHODS

Patients data were collected from case-records retrospectively. 308 case histories of children diagnosed portal hypertension were analyzed, in the period from January 2011 to January 2022, 226 (73.3%) out of which underwent surgical treatment. In 37 (16.4%) children distal splenorenal shunt (DSRS) was performed. The mean follow-up period was 55.4 ± 6.1 months.

For all patients, the following criteria were analyzed: gender, age of disease debut, variceal bleeding as initial symptom, underlying pathology, basic laboratory (thrombocytes count and hemoglobin level) and ultrasound results (initial and following spleen volume), endoscopic examination results (initial and following varices grade), recurrent bleeding episodes, shunt dysfunction. Examination was as follows: CBC with thrombocytes count, ultrasonography (US) in gray scale with spleen volume measurement (using the standard prolate ellipsoid formula: $\text{length} \times \text{width} \times \text{depth} \times 0.523$), color Doppler, and spectral Doppler tracings, using Samsung RS80A-UA, convex transducer (mean frequencies 1–7 MHz). Endoscopy was performed using endoscopes GIF-H185, GIF-Q150, GIF-XQ260, Olympus LTD, Japan. Esophageal varices grade was assessed according to Japanese Research Society for Portal Hypertension [6]. DSRS was performed according to a standard method [7] by the same surgeon.

Statistical analysis was preformed using IBM SPSS for Windows version 24.0 (IBM Corp., Armonk, NY) and EZR Statistical Software, v.1.6 (The R Foundation for Statistical Computing). Data distributions were compared (for different surgical methods) using the paired Student's t-test or Wilcoxon criteria. Kaplan-Meier estimator was used to assess shunt survival. Scheffé's test, Kruskal-Wallis and dispersion analysis were used for multiple comparisons, and Dunn test were used to compare the endoscopic follow-up results. Chi-square test was used to assess nonparametric data analysis for varices regression assessment. A P-value < 0.05 was considered statistically significant.

The Committee on Clinical Investigation

of Bogomolets National Medical University approved this study (Protocol №141 27.01.2021). All the studies were conducted according to implemented guidelines in consideration of GCP-ICH, Declaration of Helsinki and declaration of Istanbul. The written informed consent of all participants' parents/guardians was achieved.

RESULTS

Patients of the study group ($n=37, 100\%$) were divided into two groups according to etiological factor, that caused PH: 29 (78.3%) were diagnosed EHPVO, and 8 (21.7%) – HPH. The EHPVO was confirmed in all patients by ultrasound with a sonographic Doppler study of the portal system and computed tomography. Underlying liver disease when suspected was confirmed by liver biopsy before the surgery.

In EHPVO group 13(35.1%) had umbilical catheter in anamnesis because of complicated labor and delivery, that required following treatment within neonatal intensive care unit. In 24(64.9%) patients EHPVO was considered idiopathic.

In PH group biopsy showed idiopathic fibrosis in 4(50%) patients. Other diagnoses included Polycystic kidney disease accompanied by liver fibrosis ($n=2$; 25%), cystic fibrosis ($n=1$; 12.5%), and autoimmune hepatitis ($n=1$; 12.5%).

Comparison of the study groups' homogeneity according to the primary clinical, ultrasound, laboratory and endoscopic examination at initial admission are represented in Table 1.

As it is seen, no significant difference revealed between groups except the spleen volume which was greater in PHP patients ($p=0.009$) and the general follow-up of the EHPVO patients is longer ($p=0.001$). In general, most patients of both groups presented symptoms of OH, such as splenomegaly, hypersplenism (here - thrombocytopenia), anemia, high grade varices and variceal bleeding episodes.

The indications to operation were high grade (II-III), manifestation of preoperative recurrent bleeding episodes, significant splenomegaly with thrombocytopenia progression. All the patients from PHP group were additionally assessed by standard scales for end stage liver diseases [8,9] to

Table 1

Comparison of the study groups' homogeneity according to the primary clinical, ultrasound, laboratory and endoscopic data

Variable	Patients with EHPVO	Patients with HPH	P value
Sex (%) Male Female	19 (67.8%) / 9 (32.2%)	4 (50%) / 4 (50%)	0.620 ¹
Age at diagnosis (median (Q1÷Q3))	5 (3÷9)	11 (7÷16)	0.250 ²
Platelets count per mm ³ (median (Q1÷Q3))	81 (65÷121)	56 (48÷86)	0.052 ²
Hemoglobin level g/l (median (Q1÷Q3))	93.5 (82÷110)	97 (85÷106)	0.924 ²
Spleen volume (cm ³) (median (Q1÷Q3))	384 (276÷420)	863 (420÷1104)	0,009 ²
Esophageal varices grade II-III (%)	25 (89.2%) / 3 (10.8%)	6 (75%) / 2 (25%)	0.670 ³
Variceal bleeding as a debute sign(%) YesNo	19 (67.8%) / 9 (32.2%)	3 (37.5%) / 5 (62.5%)	0,266 ¹
Preoperative recurrent bleeding episodes (%) YesNo	6 (21.4%) / 22 (78.6%)	2 (25%) / 6 (75%)	0.789 ¹
DSRS dysfunction (%) YesNo	8 (28.5%) / 20 (71.5%)	1 (12.5) / 7 (87.5%)	0.634 ¹
Follow up, months (mean±SD)	61.79±7.4	30.38±4.95	0,001 ⁴

assess the stage of pathogenic process in dynamics, and surgery was considered only when the patients was assessed, as stable, with scores not more than 10 in both scales. Early postoperative period was uneventful in all patients.

DSRS dysfunction was observed in 8 (28.5%) patients from EHPVO group; shunt thrombosis, accompanied by a recurrent bleeding and splenomegaly with thrombocytopenia progression occurred in a period from 1 week to 136 months

after surgery. All patients with DSRS dysfunction underwent repeated surgeries, among which . In HPH group (n=1,12.5%) patient manifested recurrent bleeding 24 months after initial shunting procedure. DSRS thrombosis was diagnosed and splenectomy with complete portoazygos disconnection.

Kaplan-Meyer survival analysis was performed to estimate and compare DSRS survival in both groups of patients (Fig. 1).




Fig. 1. Shunt survival (Kaplan-Meier curve) for DSRS in patients with HPH (red uniform line) 0.833 95%CI(0.237-0.975), versus DSRS in patients with EHPVO (black uniform line) 0.309 95%CI(0.0186-0.708)

Median overall shunt survival was not reached by the patients of the HPH group. No difference was found in the survival between two groups ($p=0.631$).

The dynamics in laboratory tests, spleen volume, between initial admission, the first postoperative month after DSRS and the end of study period (long-term follow up) is shown in Table 2. The results were compared in pure DSRS ($n=20$ in EHPVO group and $n=7$ in HPH group), patients after repeated surgical interventions are excluded from the comparison.

Notes: 1 Kruskal-Wallis test; 2 multiple comparison, dispersion analysis; 3 Scheffe test.

DSRS resolved thrombocytopenia, anemia and decreased the spleen size in all the patients, with significant difference achieved in platelets count increase in patients of both EHPVO and HPH groups ($p=0.009$ and $p=0.021$ correspondingly) and in hemoglobin level increase in EHPVO patients ($p=0.037$)

As the first endoscopy is performed not earlier than 6 months after the surgery, endoscopy results were not included into the Table 2. By the time the study was completed, the decrease in varices grade was observed in most patients, grade I varices were registered in 14(65,5%) patients of EHPVO group and in 7(100%) in HPH group. Chi-square

test was used to analyze the varices involution and revealed the difference $p<0,001$ between initial and long-term endoscopic results in both EHPVO and HPH patients.

There was zero mortality in both study groups.

DISCUSSION

Symptomatic PH in pediatric patients manifests with life-threatening symptoms, such as variceal, and others, such as splenomegaly, hypersplenism, anemia, ascites [2,3,6,10]. bleeding EHPVO in pediatric patients is the main cause of portal hypertension [1,9]. Despite the successful development of endoscopic treatment methods, where band ligation showed its effectiveness in primary bleeding prophylaxis in pediatric patients [6], the method is temporal and does not influence the portal pressure as is [1,6,11,12], while the mortality from variceal bleeding in pediatric population remains high, assessed up to 19% [12]. Against the background of the lack of worldwide standardized surgical approaches to the PH treatment in children, all prominent clinics and authors agreed Rex(mesoportal) shunt to be the golden standard of PH surgical treatment [1-4,13,14], though since its first description it was clear favorable anatomy is required for Rex-shunt to be feasible [2,4,14].

Table 2

Comparison of the experimental groups' primary, postoperative and final US and laboratory results

Variable		Primary results	Postoperative	Final results	p-value
Spleen volume (cm ³) (median (Q1÷Q3))	EHPVO	540 (275÷689)	401 (330÷481)	386 (228÷545)	0.250 ¹
	PHP	774.4 (420.4÷1128)	494.1 (274.7÷713.5)	436.7 (256.5÷616.9)	0.084 ¹
Platelets count per mm ³ (median (Q1÷Q3)) (mean±SD)	EHPVO	79.5 (55÷102)	93.5 (78÷156)	122 (96÷168)	0,009 ¹
	PHP	67±9.8	142.1±24.4	158±27..7	0.021 ² 0.03 ³
Hemoglobin g/l (mean±SD)	EHPVO	94.8±5.4	99.25±3.7	110.1±3.08	0.037 ² 0.04 ³
	PHP	97.0±4.3	115.7±8.6	116.3±9.8	0.161 ²

Moreover, the so called “golden standard” of PH surgical treatment cannot be used in patient with HPH, as their portal vein is safe, and the shunting would not influence the resistance of liver parenchyma, and therefore, would not decrease the portal pressure [2,5,6,15]. Other surgical options are to be thought of in EHPVO patients with unfavorable anatomy and for HPH patients. In one of the earliest publications, in 1978 Maksoud et. al. described the group of 7 pediatric patients with cirrhosis and symptomatic PH, in which DSRS, end-to-side anastomosis, was considered safe and effective for leaving the intestinal portal inflow into the liver without changes [16].

Nevertheless, two of seven described shunts developed thrombosis. In later publication by Moon et. al. [17] we find a group of 10 EHPVO and 5 cirrhotic pediatric patients, in which indication to DSRS was severe thrombocytopenia, successfully treated by the shunting procedure. In general, most described groups are relatively small, with relatively short follow up period. The indications for DSRS in EHPVO patients of our study were based on peculiarities of vascular anatomy and vessels patency. As for HPH patients, DSRS is called the “bridge” to transplantation by some authors [17,18], not causing the major changes in vascular anatomy and having more positive results regarding encephalopathy in comparison to TIPS. In our study the HPH patients were selected for DSRS considering mentioned details, and their continuous liver function stability according to accepted liver end stage diseases scales. The results of current study confirmed the results of previous smaller groups regarding the ability of DSRS to resolve varices, and signs of cytopenia.

Moreover, in both groups insignificant spleen volume decrease was observed, and hemoglobin level increase, significant in EHPVO patients. At the same time, DSRS survival is to be discussed separately: in EHPVO group it was assessed 0.309 95%CI 0.0186-0.708, with 9(32.2%) cases of shunt thrombosis occurred. Authors hypothesis is – the surgical approach results into the division of the portal system into the “left” (splenic) and “right” (splanchnic), with following portal pressure increasement within the left one, and new

collaterals around spleen and pancreas appearance to compensate the high portal pressure again.

Thus it might reduce the flow within DSRS, the shunt becomes deserted and thrombosis develops. As a PH treatment option, DSRS must be considered effective in thrombocytopenia resolving and varices involution.

CONCLUSION

1. DSRS showed appropriate results in resolving dangerous symptoms of PH in both study groups with non-cirrhotic (EHPVO) and cirrhotic (HPH) causes of PH, with significant thrombocyte count increase in both groups ($p=0.009$ in EHPVO patients and $p=0.021$ in HPH patients).
2. Varices grade involution was also significant in both study groups ($p<0,001$). However, despite no difference was found in DSRS survival between study groups, DSRS survival in patients with EHPVO was 0.309 95%CI 0.0186-0.708, reaching median survival by 136 months, which might result from division of portal system into “left” and “right” with following portal pressure increasement and new collaterals appearance; thus shunt becomes deserted and thrombosis develops. Further studies are required to prove this hypothesis.

Sources of funding. The present study was supported by the Ministry of Health of Ukraine (project no. 0122U001363 “Experimental justification of portal hypertension surgical treatment method in children according to molecular, morphological, and functional changes in liver”).

Conflict of interests. The authors of this manuscript claim that there is no conflict of interest during the research and writing of the manuscript.

Acknowledgments. The author would like to thank anonymous reviewers for their useful comments and suggestions for improving the manuscript.

Consent to publish and contributions. Author conceived the study, performed experiments and analyzed the data, drafted the manuscript, revised it, critically reviewed and approved the final manuscript.

REFERENCES

1. Scholz S, Sharif K. Surgery for portal hypertension in children. *Curr Gastroenterol Rep.* 2011 Jun;13(3):279-85. DOI: 10.1007/s11894-011-0186-8. PMID: 21424236.
2. Young V, Rajeswaran S. Management of Portal Hypertension in the Pediatric Population: A Primer for the Interventional Radiologist. *Semin Intervent Radiol.* 2018 Aug;35(3):160-164. DOI: 10.1055/s-0038-1660794. Epub 2018 Aug 6. PMID: 30087518; PMCID: PMC6078695.
3. Jhang J, Li L. Rex Shunt for Extra-Hepatic Portal Venous Obstruction in Children. *Children (Basel).* 2022;9(2): 297. DOI: 10.3390/children9020297.
4. Wang RY, Wang JF, Sun XG et al. Evaluation of Rex shunt on cavernous transformation of the portal vein in children. *World J Surg.* 2017;41:1134-1142. DOI:10.1007/s00268-016-3838-x.
5. Raissi D, Brahmhatt S, Yu Q, Jiang L, Liu C. Transjugular intrahepatic portosystemic shunt for pediatric portal hypertension: A meta-analysis. *J Clin Imaging Sci.* 2023 Jun 26; 13:18. DOI: 10.25259/JCIS_36_2023. PMID: 37405364; PMCID: PMC10316155.
6. Shneider BL, Bosch J, de Franchis R, Emre SH, Groszmann RJ, Ling SC, Lorenz JM, Squires RH, Superina RA, Thompson AE, Mazariegos GV; expert panel of the Children's Hospital of Pittsburgh of UPMC. Portal hypertension in children: expert pediatric opinion on the report of the Baveno v Consensus Workshop on Methodology of Diagnosis and Therapy in Portal Hypertension. *Pediatr Transplant.* 2012 Aug;16(5):426-37. DOI: 10.1111/j.1399-3046.2012.01652.x.
7. Mitchell RL, Ignatius JA. Distal splenorenal shunt: standard procedure for elective and emergency treatment of bleeding esophageal varices. *Am J Surg.* 1988 Sep;156(3 Pt 1):169-72. DOI: 10.1016/s0002-9610(88)80057-6
8. Shinkai M, Ohhama Y, Take H, Fukuzato Y, Fujita S, Nishi T. Evaluation of the PELD risk score as a severity index of biliary atresia. *J Pediatr Surg.* 2003 Jul;38(7):1001-4. DOI: 10.1016/s0022-3468(03)00179-9.
9. Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, Kremers W, Lake J, Howard T, Merion RM, Wolfe RA, Krom R; United Network for Organ Sharing Liver Disease Severity Score Committee. Model for end-stage liver disease (MELD) and allocation of donor livers. *Gastroenterology.* 2003 Jan;124(1):91-6. DOI: 10.1053/gast.2003.50016.
10. Flores-Calderón J, Morán-Villota S, Rouassant SH, Nares-Cisneros J, Zárate-Mondragón F, González-Ortiz B, Chávez-Barrera JA, Vázquez-Frías R, Martínez-Marín EJ, Marín-Rentería N, Bojórquez-Ramos MDC, De León YAC, Ortiz-Galván RC, Varela-Fascinetto G. Guidelines for the diagnosis and treatment of extrahepatic portal vein obstruction (EHPVO) in children. *Ann Hepatol.* 2013 Jan-Feb;12 Suppl 1:S3-S24. DOI: 10.1016/S1665-2681(19)31403-6.
11. Duché M, Ducot B, Ackermann O, Guérin F, Jacquemin E, Bernard O. Portal hypertension in children: High-risk varices, primary prophylaxis and consequences of bleeding. *J Hepatol.* 2017 Feb;66(2):320-327. DOI: 10.1016/j.jhep.2016.09.006. Epub 2016 Sep 20.
12. dos Santos JM, Ferreira AR, Fagundes ED, Ferreira AP, Ferreira LS, Magalhães MC, Bittencourt PF, Carvalho SD, Figueiredo Filho PP, Penna FJ. Endoscopic and pharmacological secondary prophylaxis in children and adolescents with esophageal varices. *J Pediatr Gastroenterol Nutr.* 2013 Jan;56(1):93-8. DOI: 10.1097/MPG.0b013e318267c334.
13. Bambini DA, Superina R, Almond PS et al. Experience with the Rex shunt (mesenterico-left portal bypass) in children with extrahepatic portal hypertension. *Journal of Pediatric Surgery.* 2000; 35(1): 13-8. DOI: 10.1016/s0022-3468(00)80005-6.
14. Carollo V, Marrone G, Cortis K et al. Multimodality imaging of the Meso-Rex bypass. *Abdominal Radiology.* 2019;44(4):1379-1394. DOI:10.1007/s00261-018-1836-1.
15. Vogel CB. Pediatric portal hypertension: A review for primary care. *Nurse Pract.* 2017 May 12;42(5):35-42. DOI: 10.1097/01.NPR.0000515427.91649.91.
16. Maksoud JG, Miles S, Pinto VC. Distal splenorenal shunt in children. *J Pediatr Surg.* 1978 Jun;13(3):335-40. DOI: 10.1016/s0022-3468(78)80410-2.

17. Moon SB, Jung SE, Ha JW, Park KW, Seo JK, Kim WK. The usefulness of distal splenoportal shunt in children with portal hypertension for the treatment of severe thrombocytopenia and leukopenia. *World J Surg.* 2008 Mar;32(3):483-7. DOI: 10.1007/s00268-007-9356-0.
18. Pomposelli J, Tongyoo A, Jenkins R, Akoad M, Lewis W, Pomfret E. Distal Splenoportal Shunt (DSRS): A Durable Bridge to Liver Transplantation [abstract]. *Am J Transplant.* 2015; 15 (suppl 3).

Article history:

Received: 10.06.2024

Revision requested: 15.06.2024

Revision received: 25.07.2024

Accepted: 25.09.2024

Published: 30.09.2024

ДИСТАЛЬНИЙ СПЛЕНОРЕНАЛЬНИЙ ШУНТ ПРИ ХІРУРГІЧНОМУ ЛІКУВАННІ ПОРТАЛЬНОЇ ГІПЕРТЕНЗІЇ У ДІТЕЙ

Годік О.С.

*Національний медичний університет імені Богомольця, Київ, Україна
Національна спеціалізована дитяча лікарня «Охматдит», Київ, Україна*

ogodik@gmail.com

Актуальність. За останні роки лікування дітей із портальною гіпертензією (ПГ) значно вдосконалилося. Фізіологічне шунтування та успіхи в трансплантації печінки змінили парадигму хірургії портальної гіпертензії. Проте діти з нециротичними причинами ПГ і несприятливою анатомією, а також пацієнти з циротичними причинами потребують інших радикальних хірургічних підходів. Публікацій про педіатричні когорти, яким виконувалися інші хірургічні втручання, у тому числі дистальне спленоренальне шунтування (ДСРШ), недостатньо.

Ціль: проаналізувати ефективність ДСРШ у лікуванні найбільш небезпечних симптомів ПГ: рецидивів кровотечі з варикозного розширення вен стравоходу, спленомегалії, тромбоцитопенії та анемії, а також оцінити виживаність при ДСРШ у різних групах пацієнтів.

Матеріали та методи. Проведено одноцентрове ретроспективне дослідження. 37 дітям у період з січня 2011 р. по січень 2022 р. виконано ДСРШ. Період спостереження склав $55,4 \pm 6,1$ міс. **Conclusion.** Stress echocardiography with strain imaging during intravenous dipyridamole was an effective method for simultaneously detecting violation of the coronary vasodilatation reserve and confirming the myocardial ischemia.

Результати. Пацієнти ($n=37$ 100%) були розподілені на дві групи за етіологічним фактором, що спричинив ПГ: у 29 (78,3%) діагностовано допечінкову (ДФПГ), у 8 (21,7%) – печінкову (ПфПГ) форму ПГ. Порівняння груп показало різницю в об'ємі селезінки ($p=0,009$) і тривалості спостереження ($p=0,001$). ДСРШ усунула тромбоцитопенію, анемію та зменшила розмір селезінки в усіх пацієнтів, збільшилася кількість тромбоцитів у пацієнтів як з ДФПГ ($p=0,009$), так і з ПфПГ ($p=0,021$), а також підвищився рівень гемоглобіну у пацієнтів з ДФПГ ($p=0,037$). Порівняння ступеня варикозу показало інволюцію в обох групах ($p<0,001$). Дисфункція ДСРШ спостерігалась у 8 (28,5 %) пацієнтів групи ДФПГ та у 1 (12,5 %) пацієнтів групи ПфПГ. Виживаність ДСРШ у пацієнтів з ДФПГ оцінена як 0,309 (95% ДІ 0,0186-0,708) без різниці в загальній виживаності шунта між групами.

Висновок. ДСРШ продемонструвало добрі результати у розрешенні небезпечних симптомів ПГ в обох групах дослідження з нециротичною (ДФПГ) і циротичною (ПфПГ) причинами ПГ, зі значним збільшенням кількості тромбоцитів і інволюцією варикозного розширення вен. Однак, незважаючи на відсутність різниці у виживаності ДСРШ між групами дослідження, виживаність ДСРШ у пацієнтів з ЕНРВО досягла медіани виживання в 136 місяців.

Ключові слова: портальна гіпертензія, дистальне спленоренальне шунтування, дисфункція шунту, рецидив кровотечі з варикозних вен, діти.